Good morning, and welcome to the Omega Healthcare Investors Q2 2019 Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Michelle Reber. Please go ahead.
Thank you, and good morning. With me today are Omega's CEO, Taylor Pickett CFO, Bob Stevenson COO, Dan Booth Chief Corporate Development Officer, Steven Insoff and SVP Operations, Jeff Marshall. Comments made during this conference call that are not historical facts may be forward looking statements, such as statements regarding our financial projections, dividend policy, portfolio restructurings, rent payments, financial condition or prospects of our operators, contemplated acquisitions, dispositions or transitions, and our business and portfolio outlook generally. These forward looking statements involve risks and uncertainties, which may cause actual results to differ materially. Please see our press releases and our filings with the Securities and Exchange Commission, including without limitation, our most recent report on Form 10 ks, which identifies specific factors that may cause actual results or events to differ materially from those described in forward looking statements.
During the call today, we will refer to some non GAAP financial measures such as FFO, adjusted FFO, FAD and EBITDA. Reconciliations of these non GAAP measures to the most comparable measure under generally accepted accounting principles, as well as an explanation of the usefulness of the non GAAP measures are available under the Financial Information section of our website atwww.omegahealthcare.com and in the case of FFO and adjusted FFO in our recently issued press release. I will now turn the call over to Taylor.
Thanks, Michelle. Good morning and thank you for joining our Q2 2019 earnings conference call. Today, I will discuss our Q2 results, our recent acquisition activity, our 2019 earnings guidance and Texas Medicaid reimbursement. Our 2nd quarter adjusted FFO is $0.77 per share and we declared a $0.66 per share dividend. The payout ratio is 86% of adjusted FFO and 97% of funds available for distribution.
In May, we closed the MedEquities acquisition. All of the operational and accounting functions have been fully integrated in Hunt Valley. We are excited about the new MedEquities tenant relationships and look forward to potential new capital deployment opportunities. We have also announced our recently signed $735,000,000 purchase agreement. Dan will provide additional details later in the call.
Turning to earnings guidance. We have tightened our 2019 full year adjusted FFO guidance to a range of $3.03 to $3.07 The Titan guidance reflects the closing of the MedEquities deal, the opportunistic pending $85,000,000 sale of 10 Kentucky facilities currently operated by Diversicare and the anticipated cash rents from our Daybreak facilities. In addition, we have adjusted our 4th quarter adjusted FFO guidance to a range of $0.76 per share to $0.79 per share. The redeployment of the Diversicare sale proceeds and any improvement in our Daybreak cash rents will positively impact our adjusted FFO run rate going into 2020. Lastly, Texas remains a challenging state with very low Medicaid rates.
As Dan will detail, this is particularly difficult for rural Texas skilled nursing facilities. I will now turn
the call over to Bob.
Thanks, Taylor, and good morning. Our reportable FFO on a diluted basis was $157,000,000 or $0.71 per share for the quarter as compared to $154,000,000 or $0.74 per diluted share for the Q2 of 2018. Our adjusted FFO was $169,000,000 or $0.77 per share for the quarter and excludes several items as outlined in our adjusted FFO reconciliation to net income found in our earnings release, our website and on our supplemental. Operating revenue for the quarter was approximately $225,000,000 versus $220,000,000 for the Q2 of 2018. The increase was primarily a result of incremental revenue from a combination of over $850,000,000 of new investments completed and capital renovations made to our facilities since the Q2 of 2018, as well as lease amendments made during that same time period.
Revenue related to the Orianna facilities that were transitioned to existing Omega operators in the 3rd 4th quarters of 2018 and finally, we adopted the new lease accounting standard effective January 1, 2019, which resulted in the recording of tenant real estate taxes and ground lease income in revenue. The increase in revenue was partially offset by reduced revenue related to asset sales, transitions and loan repayments that occurred throughout 2018. The timing of cash receipts related to operators on a cash basis and finally, based on the interpretation of the collectability guidance the new lease accounting standard requiring the write off of straight line receivables for operators on a cash basis, we recorded approximately $6,700,000 for non collectible revenue related to 2 operators during the quarter. The $225,000,000 of revenue for the quarter includes approximately $17,000,000 of non cash revenue. Our G and A expense was $9,500,000 for the Q2 of 2019 versus $11,100,000 for the Q2 of 2018, with the reduction resulting from reduced workout and restructuring related expenses.
Interest expense for the quarter, when excluding non cash deferred financing costs, was $48,000,000 or approximately the same as the Q2 of 2018. For 2019 guidance and modeling purposes, we are assuming the following major assumptions. For MedEquities, the acquisition was completed on May 17 and as a result, our 2nd quarter results had $7,100,000 of revenue from MedEquities or half a quarter. We issued 7,500,000 Omega common shares as part of the acquisition and approximately $350,000,000 of additional credit facility debt related to the payoff of their credit facility and the cash portion of the purchase price to their shareholders. We assume new construction projects will be put into service in accordance with our schedule on Page 7 of our supplemental information posted on our website.
We assume revenue from Daybreak will continue to be recorded on a cash basis with revenue of $3,000,000 to $5,000,000 per quarter. We assume non cash quarterly revenue should be between 16 $1,000,000 $18,000,000 per quarter. We project our G and A for the remaining quarters of 2019 to be consistent with our 2nd quarter or $9,000,000 to $10,000,000 per quarter. Non cash stock based compensation expense is estimated to continue at approximately $4,000,000 per quarter. The variability in our interest expense is primarily driven by borrowings on our credit facility and LIBOR rates.
At June 30, 24 percent of our debt or $1,000,000,000 was floating rate debt. We assume that disposition of the 10 Diversicare assets will occur by the end of the Q3. And although not included in guidance, additional asset disposition opportunities may occur. The $735,000,000 potential acquisition is not included in the 2019 guidance. Regarding share issuances, in addition to the 7,500,000 Omega common shares issued for MedEquities in the 2nd quarter, we assume we will be issuing approximately $15,000,000 to $25,000,000 of equity per quarter through our dividend reinvestment and common stock purchase plan, consistent with our recent quarterly issuances.
Lastly, based on our stock price and subject to equity market conditions, we may decide to issue equity on our ATM to continue to delever and fund potential acquisitions. During the 1st 6 months of 2019, we issued or sold approximately 4,400,000 shares of Omega common stock, generating $159,000,000 in gross proceeds through a combination of our ATM and our dividend reinvestment in common stock purchase plans. Our balance sheet remains Our balance sheet remains strong. At June 30, approximately 76 percent of our $4,700,000,000 in debt is fixed and our net funded debt to adjusted annualized EBITDA was 5.37 times and our fixed charge coverage ratio was 4.06 times. It's important to note EBITDA on these calculations has no revenue related to construction and process associated with our 6 new builds scheduled to become operational in the next 12 months.
When adjusting for a full quarter of MedEquities and the known revenue on our new builds, our pro form a leverage would be roughly 5 times. I will now turn the call over to Dan.
Thanks, Bob, and good morning, everyone. As of June 30, 2019, Omega had an operating asset portfolio of 9 30 facilities with approximately 93,000 operating beds. These facilities were spread across 75 third party operators and located within 40 states in the United Kingdom. Trailing 12 month operator EBITDARM and EBITDAR coverages for our core portfolio dipped slightly during the Q1 of 2019 to 1.67 and 1.31 times respectively versus 1.67 and 1.32 times respectively for the trailing 12 month period ended December 31, 2018. Turning to portfolio matters.
On September 1, 2017, Omega placed 1 of its top 10 operators Daybreak on a cash basis for revenue recognition purposes due to operational challenges and liquidity issues. As a result of these concerns, Omega and Daybreak consensually entered into a settlement and forbearance agreement on October 30, 2017, which was amended and extended effective January of 2019, whereby we granted Daybreak a $2,500,000 rent deferral for the 1st 2 quarters of 2019. With the exception of $1,100,000 in required real estate tax escrows, Daybreak met their contractual obligations through the Q2 of 2019. However, continued pressures on overall occupancy, Medicare census and labor costs have resulted in even tighter liquidity and accordingly we have not recognized any income to date in the Q3 of 2019. Compounding these ongoing pressures and as Taylor mentioned, the Texas State Legislature recently failed to pass a bill which would have provided Texas nursing home operators much needed Medicaid rate relief.
Confronted with these challenges, Omega recently engaged a 3rd party consultant to provide a comprehensive review of Daybreak's overall operations, provide commentary and recommendations for improvement opportunities and provide a long range forecast for future cash flow expectations. While the ultimate results of our consultants' findings are not yet final, we are adjusting our expectations for future cash rent receipts to a range of between $3,000,000 $5,000,000 per quarter for the foreseeable future. It is important to point out, however, that this remains work in progress and in no way reflects our future rent expectations for this portfolio as we continue to work with Daybreak's management team and our 3rd party consultants to maximize Daybreak's future cash flow and thus fine tune our rent forecasts. While many of our Texas operators are challenged by Texas's woefully low Medicaid rate and the continued labor pressures, Daybreak is further challenged given its widespread geographical footprint across the entire state, its lack of exposure to any other better reimbursement states and its mostly rural localities resulting in limited Medicare Q mix and low occupancy. While the 3rd quarter is expected to be a particularly challenging one, we are confident that Daybreak will benefit from several known factors in the Q4, including the addition of 26 Omega facilities into the Texas QIP program, the implementation of PDPM and the 2.4% Medicare rate increase.
The quit benefit begins September 1, while PDPM and Medicare rate increases take effect on October 1. The results of these benefits as well as our ongoing discussions with Daybreak and our consultants' recommendations will greatly assist Omega in our future forecasts and our ultimate restructured plans. Turning to new investments. As mentioned by Taylor, we closed on our acquisition of MedEquities on May 17, 2019 for total consideration of $623,000,000 The MedEquities portfolio consisted of 35 facilities located in 8 states with 12 different operators, 10 of which are new to Omega. We believe this portfolio will provide Omega with new opportunities as well as the potential to expand into new asset classes.
In addition to the MRT acquisition, Omega invested $55,500,000 in capital expenditures during the Q2 of 2019. Turning to subsequent events. In July of 2019, Omega completed a $25,000,000 purchase leaseback for 3 skilled nursing facilities in North Carolina and Virginia. The facilities were added to an existing operators master lease for an initial cash yield of 9.5%. Also as mentioned earlier, on July 26, 2019, Omega entered into a purchase and sale agreement for the acquisition of 60 facilities for $735,000,000 consisting of approximately 3 $45,000,000 of cash and the assumption of approximately $390,000,000 of HUD debt.
The facilities comprised of 58 skilled nursing facilities and 2 assisted living facilities are leased to 2 operators via 3 triple net leases generating approximately $64,000,000 in 2020 annual cash revenue. Completion of the transaction is subject to consent by HUD as well as the satisfaction of customary closing conditions. An executed non disclosure agreement limits our ability to share additional details of this transaction at this time. I will now turn the call over to Jeff.
Thanks, Dan, and good morning, everyone. Florida's average nursing home Medicaid rate dropped 4.5% effective July 1, 2019, resulting from the loss of one time discretionary funding applied to October 1, 2018 rates to cover the impact of hold harmless provisions in the new prospective payment system or PPS enacted at that time. The new PPS basically changed the rate methodology from cost based to price based and was designed to be budget neutral. However, because 44% of Florida SNFs would have immediately suffered Medicaid rate decreases upon implementation of the new PPS, additional discretionary funding was allocated to allow SNFs to be paid the higher of their actual rate as of September 30, 2016, or the rate calculated pursuant to the new PPS subject to a cap. This hold harmless provision extends through September 30, 2021, after which SNF rates are expected to be based exclusively on the PPS, which benefits the more cost efficient providers with good quality outcomes.
The fiscal year 20 nineteen-twenty loss of discretionary funding, directly attributable to unanticipated state spending increases for hurricane relief, was allocated to the 56% of facilities whose PPS rates were above hold harmless levels, resulting in average rate decreases for those facilities of about 7%. However, the impact of these decreases was essentially to change rates back to their pre PPS levels just 9 months prior, such that operational adjustments to maintain coverage levels could be made effectively. A smaller discretionary increase effective October 1, 2019 will bump those facilities rates back up by 1.5%. As for the rest of the nation, based on the June 2019 report of the National Association of State Budget Officers, the general economic outlook for all states projects a healthy average general fund growth rate of 3.7% for fiscal year 20 nineteen-twenty, a comparable average increase in overall Medicaid spending of 4.0 percent with the state portion to increase 3.1 percent and record high rainy day funds with a median reserve balance equal to 7.5% of general fund spending. None of the states reported budgeted nursing home Medicaid rate decreases.
As a result, aside from the unique Florida rate cut, we expect nursing home Medicaid rates to generally keep pace with the growth in operating expenses for Medicaid beneficiaries. I will now turn the call over to Stephen.
Thanks, Jeff, and thanks to everyone on the line for joining today. In conjunction with Maplewood Senior Living, we continue to work on our ALF memory care high rise at Second Avenue and 93rd Street in Manhattan. The project is expected to cost approximately $285,000,000 including accrued rent and is scheduled to open in early 2020. Including the land and CIP of our New York City project, at the end of the second quarter, Omega Senior Housing Portfolio Totaled $1,600,000,000 of investment on our balance sheet. Anchored by our growing relationship with Maplewood Senior Living and their best in class properties as well as health care homes and Gold Care in the U.
K, our overall senior housing investment now comprises 127 assisted living, independent living and memory care assets in the U. S. And U. K. On a standalone basis, the core portfolio not only covers its lease obligations at 1.19x, but also represents one of the larger senior housing portfolios amongst the publicly listed health care REITs.
Our ability to successfully continue to grow this important component of our portfolio is highlighted by our 15 Maplewood facilities, including the newly opened 98 Unit ALF in Southport, Connecticut as well as the related pipeline is predicated on coupling our tenants' operating capabilities with our commitment to having in house design and construction expertise. Through the same capability, we invested $55,500,000 in the 2nd quarter in new construction and strategic reinvestment. $40,300,000 of this investment is predominantly related to our active construction projects with a total budget of approximately $500,000,000 inclusive of Manhattan. The remaining $15,300,000 of this investment was related to our ongoing portfolio CapEx reinvestment program. I will now turn the call over to Taylor for some final comments.
Thanks, Stephen. We've been clear in our intention to move back to our traditional accretive growth model in 2019. And between the deal announced today and our recently closed MedEquities acquisition, we are executing on that plan. We will continue to look to augment our portfolio with additional accretive acquisitions, while also generating further value through our robust development pipeline. We will now open up the call for questions.
Thank you. We will now begin the question and answer session. Our first question comes from Karin Ford with MUFG Securities. Please go ahead.
Hi, good morning. I wanted to ask around some question around the Daybreak resolution and the Diversicare sales. Following these, how's the visibility into future operator issues? Are you comfortable that negative headline risk around your operators is going to be ebbing in the coming quarters?
Yes. I mean, listen, the neighborhood issue, quite frankly, has been an issue now for going on close to 2 years. The Diversicare situation is one where we're looking to get them out of a state where they probably shouldn't be in. So I think that's a win win for both companies. As far as other issues on the horizon, at this point, we see nothing of any materiality.
So all clear from this standpoint.
Okay, great. I know you're unable to share a lot of additional detail on the pending acquisition, but can you tell us how it was sourced? How does it compare just generally quality and credit wise with your existing portfolio? When do you think it will close and what are your funding plans for the cash portion?
I can't describe how it was sourced. I will tell you that its coverage is slightly above our current mean. And expectations of closing is hard to predict because really is contingent upon the assumption of HUD debt, which once again it's a government agency and I'm not able to pin them down on their timing. So I think we have a pretty wide range of between 3 and as far as maybe it's outside of 9 months for the closing to take place.
Great. And then just lastly, on the financing side, you have about $500,000,000 out on your line. Should we be modeling a debt deal later this year to term that out? And are you considering a refinancing of any of your 2022 term loans given the low rates?
Our historical practice is we use our credit facility to lever up and do acquisitions. And then once it gets to a certain 500 plus 1,000,000, we always look to term it out. So I can't tell you whether we're doing 1 or not, but we will be opportunistic at the market given the current rate environment. But going back to your other question, how do we the follow-up on how we plan to finance the potential deal, well, a piece of it is assuming HUD. The second piece is we will use our credit facility, but we also have the proceeds coming in from the VersaCare sale.
Is the bond deal included in your guidance range?
It is not.
Okay. Thank you.
Our next question comes from Jonathan Hughes with Raymond James. Please go ahead.
Hey, good morning. What's the pipeline look outside of that portfolio under contract? I know you did another $2,500,000,000 of acquisitions at a 9 $5,000,000 yield at the start of July. Just curious how many more of those single and double type acquisitions to use a baseball analogy are in the pipeline?
We're constantly looking at those signals, if you will. They're always in our pipeline. They're choppy in terms of when we receive them and when we close upon them. But I would just say that it's consistent with what we've seen in the past. The bigger deals obviously are even more choppy if I may say.
The big deal that we just announced it wasn't even on our radar screen 6 months ago. So they're very, very hard to predict.
Okay. Maybe I'll turn to Texas and obviously legislation expected to address Medicaid reimbursement rates didn't happen there. How do you view that state over the next few years in terms of your current exposure and investment potential? I mean, any plans to pair exposure there? You did mention there could be more dispositions in the back half of the year.
Or do you see those headwinds creating potential growth opportunities as some people struggle and you can create some value for shareholders.
Yes. I think, Keith, just to hit it with the latter point. I mean, listen, we're not going to be aggressive in acquiring facilities in Texas. But if one of our existing operators sources a deal and comes to us, we'll do everything we can to meet those needs. So and we are going to be opportunistic in Texas because I do think there'll be some opportunities.
Okay.
Is there any chance the legislature would readdress that before 2021 or are we stuck here for 2 years with the current rate policies?
So they were trying to do something unique. I mean, I don't want to they're trying to tap federal funds with this recent legislation. So it was a little bit unique. It was they were trying to pass a specific bill. That doesn't preclude Texas from granting just flat out Medicaid rate increases, which could occur within the next 2 years.
Okay. So maybe a chance for some upside. All right. One more for me since it's in my backyard. Can you expand upon the Florida Medicaid legislation you talked about earlier?
Basically, I just want to understand the risk to your Florida portfolio. That's 9% of the overall company. Maybe what's coverage within your Florida segment and where do you expect that to go maybe over the next 12 months or so?
The coverage in Florida is probably slightly above the mean. And it was helped by the switch from cost base to PPS. So it actually got a pickup. And I think now this is going to sort of slip back down again. But most of the operators there have accounted for this and most of them have dealt with it in terms of making some corporate cuts to bring cost back in line with the new rates.
Okay. All right. That's helpful. I'll jump off. Thanks for the time.
Our next question comes from Lukas Hartwich with Green Street Advisors. Please go ahead.
Thanks. Good morning. Can you provide the skilled mix and EBITDARM margin on the $735,000,000 portfolio?
Off the top of my head, no. I think it's north of 20%. And then did you ask what was the second one, the EBITDAR coverage?
EBITDARM margin?
EBITDARM would be slightly above the mid theme for the entire portfolio.
Okay. And then are there any tenanting plans with that
portfolio? No.
Okay. And then lastly, can you provide the rent bumps?
There are more than one portfolio. I believe 1 is 2.25 and 1 is 2.5.
Okay. That's it for me. Thank you.
Our next question comes from Trent Giulio with Scotiabank. Please go ahead.
Hi, good morning. So just following up on a topic from a little bit earlier and market exposure. With Diversicare exiting Kentucky and some news about other operators leaving states like Ohio and the issues that have been documented in Texas, can you give us your thoughts on market diversification where you'd optimally like to add or remove exposure?
In general, Trent, I would say that we continue to focus on the Southeast and the Far West. The middle of the country, we've lightened up already. Kentucky is somewhat unique because it's a pretty good reimbursement state, but the professional liability exposure there makes it a dangerous state, particularly for public operators like Diversicare. So that's a little bit of a unique situation. Kentucky in general is a pretty good state.
So that's kind of broad brush. The Northeast has not been nor will it be a focus for the next year or 2.
Okay. So I guess triangulating that, is it fair to say the $735,000,000 acquisition is focused on markets such as that, like in the Southeast?
That is fair to say, Trent. Yes.
Okay. I guess sticking with Diversicare, they reported some, I guess, somewhat less than inspiring results earlier this week. And even after your sale of 10 assets in Kentucky, you still have exposure to, I believe, 20 4 other assets of theirs that they operate. So how are you viewing that relationship?
We've had a long all of long relationship with Diversicare and they've always had a tough balance sheet situation and their cash flows have tightened a bit, but we think the balance of the portfolio that we sit with will continue to perform. I can't speak specifically to their overall balance sheet issues, but ultimately, we look to the facility level of credit, which we think will continue to be relatively strong.
Okay. Shifting a little bit, looking at your operator EBITDAR coverage stratification, looks like about $28,000,000 dropped down 1 bucket
into the 1 to
1.2 times range. Can you talk about into the 1 to 1.2 times range. Can you talk about that shift and maybe how much rent is on the cusp of shifting either up or down? So I know that can change quarter to quarter. Yes.
And that's exactly what we're seeing. And I know that can change quarter to quarter.
Yes. And that's exactly what happened in this past quarter. We had somebody that was right on the cusp that was right above the 1, 2, 1, 12, 12 below. At any time, we've got some folks on the fringe. I don't have the dollar amount of rent associated with those that whatever we would define as on the fringe, but it's not an immaterial number.
It's probably somewhere between the $25,000,000 $50,000,000 of rent.
That is on the fringe that could shift?
Well, it depends on how
you define fringe, but yes.
Okay, sure. Okay. Are those numbers inclusive of the MedEquities properties? Did that portfolio did absorbing that portfolio affect your stratification much?
It didn't affect at all because it's not incorporated. We closed on that in mid May. So it would be even after the coverages that we were reporting on. So no, but the MedEquities portfolio in general is slightly has slightly higher coverages than the legacy Omega, although it wouldn't it's not enough to move the needle.
Okay. And I'm sorry, one more one last one for me, if you don't mind. So given all the completed and announced acquisitions, how are you thinking about your dividend on a go forward basis?
Yes. So as we've discussed in the past, Trent, we'll look at it every quarter as a Board. At this point with dividend coverage in the 90s, I wouldn't expect to see a shift in our dividend policy. But again, the Board takes it up every quarter. And we do have a number of assets coming online that are going to produce pretty significant cash between Second Avenue and the closing of the transaction we announced today and the timing of that will drive a lot of decision making.
Okay. Thank you very much. Appreciate it.
Our next question comes from Daniel Bernstein with Capital One. Please go ahead.
Hey, good morning. I wanted to go back to how you're thinking about your role versus urban exposure in Texas, just following up on your earlier comments.
I think as it relates to Texas, you're sort of making the point. I mean, you have rural facilities that will continue to be relatively difficult. But we'll continue to look at opportunities in Texas just based on risk adjusted analysis. So I wouldn't say that we're making a distinction between rural and urban in terms of allocating capital, but we will risk adjust rural in a different way than we do urban.
Okay.
I don't know
if you could talk about your actual exposure referral versus urban? If not, we can always take that offline.
Yes. It really goes back to how you decide to define it. But I will tell you, we think about our overall portfolio is about 20% to 25% rural. But again, it depends how you decide to define.
Okay.
Kind of switch gears a little bit to seniors housing. You have a development pipeline with Maplewood. Are you actively looking or seeking out other operators to maybe build other development pipelines with them? I guess some of your peers have done that. Just trying to get your kind of your proclivity at this point to do more seniors housing development and expand that beyond Maplewood?
We continue to look for opportunities on the development front across the spectrum of potential operators. But I will tell you from our perspective, the Maplewood relationship is incredibly important and we're doing everything we can to turbocharge that if you will.
Does rising construction or labor costs temper any of that enthusiasm that you've developed at this point? Or is everything still kind of penciling out? Whatever's kind of what's on the drawing board maybe hasn't turned dirt yet, but you're working on, are those still penciling out as developments you want to go forward within our accretive?
They are generally. But Stephen, do you want to take
a shot at that? Yes. I think it's fair to say that construction costs in particular are putting a little bit of pressure on the excitement level around some of these new builds, but we haven't got to the point yet where they don't pencil out. They're just, I mean, slightly less exciting than they were a year ago, but it's something we're particularly careful about. And the labor costs, I think you had mentioned also, are not really swaying in one way or the other.
Okay. I appreciate it. I'll hop off and let some others ask questions. Thanks.
Our next question comes from Chad Vanacore with Stifel.
So how do you think upcoming implementation of PDPM is impacting the
pipeline in the next 6 months?
Any noticeable acceleration or deceleration of opportunities?
No, at this point, Pat. Well, not that we can directly tie to PDPM, that's for sure. So I'd say no.
So you can say that, Dan, after you sign a $700,000,000 deal?
Not sure that
was the driving force.
Yes. All
right. And then just looking across your operators, what
are you seeing in terms of census trends?
So, Medicaid census has been slowly but surely picking up. Medicare has been flat or even still slightly dropping off just because I think just the length of stay, they're not coming back up certainly and they're probably still creeping down a little bit. So overall census is flat to slightly up and it's mostly driven by Medicaid.
Okay. And then just one more question probably for Stephen. Can you give us an update on second half development with Maplewood? Where is leasing so far? You're right before opening, you plan on opening in the Q1.
So can you give us an idea of how the lease up is going?
Sure, Chad. I think the best way to describe it is that the momentum behind and I would call it deposits at this point for leases rather than leases because the building is still a number of months away from being opened. But the momentum of the deposits being taken is consistent with the levels we would see in the suburban locations that Maplewood has executed really well on in the past. So we're cautiously optimistic. The market is accepting the pricing.
So obviously, more to follow as the opening day comes closer.
Our next question comes from Todd Stender with Wells Fargo.
My question to do with the new portfolio announcement you made. So demographics and potential bottoming and sniff fundamentals, if you subscribe to that, are right now here in 2019. Are you acquiring the in place leases?
So
how do you guys participate in that and how did you kind of underwrite that?
So we are going effectively in place leases, so the rent is locked. If the operations improve, our coverage is improved, but there's no rent share, there's no revenue share.
Right. Did you enter at maybe a lower rent coverage than you normally would with the backdrop of improving fundamentals or how did you look at that?
No, I think we underwrote it to our normal standards.
Okay. And back to Daybreak, so they dropped out of your top 10 tenant list in the quarter. Did their cash rent contribution drop out mathematically? Or was this something you proactively pulled them out of? Just speak maybe speak to Daybreak.
Well, it's based on the cash rent run rate we've had this year, which is at $5,000,000 a quarter and we've talked about $3,000,000 to $5,000,000 So when you think about that on an annualized basis, they just they don't they won't be in the top 10. Hopefully, over time, we can push them back towards the top 10. We'll just have to wait and see.
Okay. Last question, Bob. I think you gave or you indicated was it 25,000,000 dollars of new equity a quarter was kind of a DRIP program estimate? Correct. Is it fair to say
I think it was based off the recent couple of quarters. Sorry about that.
Okay. Yes, no problem. The reason I ask is, is it fair to assume maybe not as much new equity raised outside of that DRIP until you've gotten through your asset sales, which include the Diversicare, you'll chew through the dispositions before we should assume maybe larger equity raise?
That's a fair assumption.
Great. Thank you.
Our next question is a follow-up question from Karin Ford with MUFG Securities. Please go ahead.
Hi. Just a couple of quick ones. You mentioned a pivot back to accretive external growth this year. 2019 is turning out to be an above average year for you guys, dollars 1,400,000,000 $1,500,000,000 maybe more to come. Should we be thinking about this volume level as the new normal for OHI or would you say that this year has been an anomaly given the 2 large transactions you've done?
So to an earlier comment that Dan made, it's something we've talked about a lot. We typically think about $400,000,000 or $500,000,000 of deal flow is naturally coming out of the relationships that we have. That seems to be a normal minimum capital allocation that we see in the portfolio. And then incrementally, it's these larger deal driven opportunities. And so if you look over time, Karen, I think the best way I think about it is if we do $1,000,000,000 in a year, that's a pretty good year and it averages out over time in that range.
So I would think about $1,500,000,000 is more than an average year. That being said, with the type of activity we've seen in 2019, I think there are a lot of reasons to believe we might see similar things in 2020.
Great. And then just sorry if I missed this, do you guys did you guys give an estimate to how much you think PDPM and the Medicare rate increase might lift overall coverage in your portfolio?
We have talked about that in the past, and it's specific by operator, but it's positive for each of the operators, at least the last time we modeled it and we modeled between 0.02 of coverage improvement to 0.11 of coverage improvement with the overall being about the average of those two numbers.
Perfect. Thank you.
This concludes our question and answer session. I would like to turn the conference back over to Taylor Pickett for any closing remarks.
Thanks, Brandon. Thanks everyone for joining the call today. As always, we're available for follow ups. I would ask you to call either Bob or Matthew if you have any specific questions. Thanks again.
The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.